Column Group’s eFFECTOR Therapeutics, Inc. Common Stock EFTR Stock Holding History

Column Group’s Portfolio EFTR Stock Details EFTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-161,049	Closed	-$2.42M	–	7
2023 Q3	$2.42M	Sell	161,049 -11,324	-7%	-$197K	1.6%	7
2023 Q2	$3.58M	Hold	172,373	–	–	1.39%	7
2023 Q1	$1.52M	Hold	172,373	–	–	0.55%	7
2022 Q4	$1.84M	Hold	172,373	–	–	0.61%	7
2022 Q3	$2.46M	Hold	172,373	–	–	0.55%	7
2022 Q2	$6.12M	Hold	172,373	–	–	1.3%	7
2022 Q1	$17.3M	Hold	172,373	–	–	3.2%	7
2021 Q4	$35.7M	Hold	172,373	–	–	4.85%	7
2021 Q3	$60.5M	Buy	+172,373	New	+$55.6M	6.89%	6

Other funds holding EFTR

Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $143M AUM 102.52% 1-Year Est. Return

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

SIMG

Sonora Investment Management Group Tucson, Arizona $1.41B AUM 20.58% 1-Year Est. Return

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

TSS

Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return

Column Group's EFTR Position: Q4 2023 in Review

Column Group sold out of eFFECTOR Therapeutics, Inc. Common Stock (EFTR) in Q4 2023, closing a stake of 161,049 shares — an estimated $2.42M sold.

Column Group first reported a position in EFTR in Q3 2021 and held it in 9 quarters. The position peaked at $60.5M in Q3 2021. 25 funds tracked by Wall St. Rank hold EFTR as of Q4 2023.

Column Group reported no remaining eFFECTOR Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Column Group sold 161,049 eFFECTOR Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $2.42M.
Column Group first reported a position in eFFECTOR Therapeutics, Inc. Common Stock in Q3 2021 and held it in 9 quarters.
Column Group's eFFECTOR Therapeutics, Inc. Common Stock position peaked at $60.5M in Q3 2021.
25 funds tracked by Wall St. Rank held eFFECTOR Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Column Group's 13F filing for Q4 2023, filed 9 Feb 2024.